Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
40 hedge funds and large institutions have $42.8M invested in Vincerx Pharma, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 5 closing their positions.
268% more capital invested
Capital invested by funds: $11.7M → $42.8M (+$31.2M)
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
25% more funds holding
Funds holding: 32 → 40 (+8)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$3.16M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.93M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$485K |
| 4 |
EP
Eversept Partners
New York
|
+$251K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$226K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.41M |
| 2 |
LFCM
Long Focus Capital Management
San Juan,
Puerto Rico
|
-$1.3M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$1.21M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$750K |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
-$275K |
VINC Hedge Fund Activity: Q1 2024 in Review
40 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2024, worth a combined $42.8M — up 268% from $11.7M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VINC positions and 5 closed out — a net gain of 9 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $3.16M. The largest seller was Goldman Sachs, cutting an estimated $3.41M.
- 40 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2024, up from 32 in Q4 2023.
- Funds reported $42.8M of Vincerx Pharma, Inc. Common Stock stock for Q1 2024, up 268% quarter-over-quarter.
- 14 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2024 and 5 closed out, a net change of +9 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2024 was Octagon Capital Advisors, an estimated $3.16M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2024 was Goldman Sachs, an estimated $3.41M sold.
Based on aggregated 13F filings for Q1 2024.